BioSpace News Archive

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, continues to receive inquiries regarding the potential of Brilacidin, the Company’s novel defensin mimetic compound, to treat COVID-19, more generically called “coronavirus,” given the urgent worldwide need to discover treatments and vaccines for the deadly epidemic.

Spherix Incorporated (Nasdaq: SPEX) today announced it has executed an exclusive option agreement (“Option”) with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 “Methods of Treating Coronavirus Infection.

RAFARMA PHARMACEUTICALS INC. “OTC:(RAFA)” Dear Shareholders: Since a recent teleconference call was held with shareholders there have been many things that have taken place

Article 223-16 of general regulation of French Autorité des Marchés Financiers

The innovator of MR-guided focused ultrasound is scaling to meet the growing demand for incisionless surgery

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce that it will set aside some of its NP-120 (Ifenprodil) drug supply from its planned phase 2 study for idiopathic fibrosis and chronic cough, to make it available on a compassionate use basis, to physicians and their patients with the most serious cases

The American Pharmacists Association (APhA) recommends that patients and/or caregivers ensure that they have adequate supplies of necessary medications to address their needs if not able to get to the pharmacy because of coronavirus

National HealthCare Corporation announced its support for, and compliance with, the Centers for Medicaid & Medicare Services infection control requirements, as well as the guidelines from the Centers for Disease Control and Prevention.

Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that it has closed its previously announced underwritten public offering of 9,798,000 shares of its common stock, including 1,278,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $23.50 per share.

Company has immediately initiated Coronavirus program Leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s ongoing research and development efforts